Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Existing bitter medicines for fighting 2019‐nCoV‐associated infectious diseases
Xiangqi Li, Chaobao Zhang, Lianyong Liu, et al.
The FASEB Journal (2020) Vol. 34, Iss. 5, pp. 6008-6016
Open Access | Times Cited: 49

Showing 26-50 of 49 citing articles:

Chlorpheniramine Intranasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: The ACCROS Trials
Fernando Valerio-Pascua, Estela Jackeline Pineda Mejia, Mari Tesch, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 4
Inflammatory pathways and potential therapies for COVID-19: A mini review
Areeg M. Dabbish, Nouran Yonis, Mohamed Salama, et al.
European Journal of Inflammation (2021) Vol. 19
Open Access | Times Cited: 5
Psychotropics and COVID-19: An analysis of safety and prophylaxis
Hervé Javelot, Céline Straczek, G. Meyer, et al.
L Encéphale (2021) Vol. 47, Iss. 6, pp. 564-588
Open Access | Times Cited: 5
The influence of bitter-taste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19
Lígia Moriguchi Watanabe, Izabella Ferreira Pires, Natália Yumi Noronha, et al.
Clinics (2020) Vol. 75, pp. e2181-e2181
Open Access | Times Cited: 4
A Novel Use for an Old Drug: Resistance Reversal in Candida Albicans by Combining Dihydroartemisinin with Fluconazole
Hui Li, Hai‐Sheng Chen, Wenna Shi, et al.
Future Microbiology (2021) Vol. 16, Iss. 7, pp. 461-469
Closed Access | Times Cited: 4
Ethnopharmacological nexus between the traditional Thai medicine theory and biologically based cancer treatment
Ponlawat Maki, Arunporn Itharat, Pakakrong Thongdeeying, et al.
Journal of Ethnopharmacology (2021) Vol. 287, pp. 114932-114932
Closed Access | Times Cited: 4
New values of a type 2 taste receptor TAS2R14 in thyroid cancer
Lianyong Liu, Qingyun Zhu, Hong Du, et al.
Acta Biochimica et Biophysica Sinica (2022) Vol. 54, Iss. 4, pp. 587-589
Open Access | Times Cited: 3
Potential of ATP5MG to Treat Metabolic Syndrome-Associated Cardiovascular Diseases
Lianyong Liu, Xinglu Zhou, Juan Chen, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 3
Uso de dextrometorfano como factor riesgo para inicio de oxigenoterapia en pacientes COVID-19 en Lima, Perú
Yeisson Rivero-Moreno
Gaceta Médica de Caracas (2024) Vol. 132, Iss. 1
Open Access
Cymatics Cup: Shape-Changing Drinks by Leveraging Cymatics
Weijen Chen, Yang Yang, Kao-Hua Liu, et al.
(2024), pp. 1-19
Open Access
Regulation of Blood-Testis Barrier Tight Junction Protein Expression in TM4 Cells by Bitter Taste Receptor Tas2R143-Induced NF-κB Signaling Pathway
Xue Wang, J. Wang, Xin Li, et al.
Theriogenology (2024) Vol. 227, pp. 120-127
Closed Access
Swertiamarin and sweroside are potential inhibitors of COVID-19 based on the silico analysis
Wenxiang Wang, Ying Tan, Jingxin Mao, et al.
Medicine (2024) Vol. 103, Iss. 45, pp. e40425-e40425
Open Access
The Bitter Taste Receptor TAS2R14 as a Drug Target
Lukas Waterloo, Stefan Löber, Peter Gmeiner
CHIMIA International Journal for Chemistry (2022) Vol. 76, Iss. 5, pp. 418-418
Open Access | Times Cited: 2
The Bitter the Taste, The Better is the Medicine: Is Caffeine the Answer to COVID-19?
Devyani Sharma, Ashutosh Bansal
(2020)
Open Access | Times Cited: 2
Publishing coronavirology: Peering into peer(less?) review
Thoru Pederson
The FASEB Journal (2020) Vol. 34, Iss. 8, pp. 9825-9827
Open Access | Times Cited: 2
Chloroquine and COVID-19: role as a bitter taste receptor agonist?
Belaïd Bouazza, Idir Ramdani, Rachid Chahed
New Microbes and New Infections (2021) Vol. 40, pp. 100843-100843
Open Access | Times Cited: 2
Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage
Suruchi Gupta, Prosenjit Paul, Ravail Singh
Gene Reports (2021) Vol. 24, pp. 101185-101185
Open Access | Times Cited: 2
Developing drugs targeting CX3CL1 to treat heart diseases via immune/inflammatory mediation
Lin Zou, Junhua Ma, Guiying Hu, et al.
Acta Biochimica et Biophysica Sinica (2023) Vol. 55, Iss. 10, pp. 1672-1676
Open Access
Regulation of Blood-Testis Barrier Tight Junction Protein Expression in Tm4 Cells by Bitter Taste Receptor Tas2r143-Induced Nf-Κb Signaling Pathway
Xue Wang, Jindan Wang, Xin Li, et al.
(2023)
Closed Access
Deciphering GABBR1-centered drug targets to fight viral infection with preexisting diabetes
Xiangqi Li, Hao Xue, Peng Li, et al.
Acta Biochimica et Biophysica Sinica (2023) Vol. 55, Iss. 12, pp. 1999-2003
Open Access
The potential of caffeine contained in the coffee to modulate the immune system of the COVID-19 sufferers: A review
Anis Irmawati, Mochamad Daffa Athallah, Retno Indrawati Roestamadji, et al.
World Journal of Advanced Research and Reviews (2023) Vol. 20, Iss. 2, pp. 1385-1400
Open Access
Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage
Suruchi Gupta, Ravail Singh, Prosenjit Paul
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access
What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects
Isabel Fambuena-Muedra, Marta Jiménez‐García, Sarah Hershko, et al.
European Journal of Ophthalmology (2020) Vol. 31, Iss. 2, pp. 291-303
Open Access
Famotidine and Treatment of COVID-19 Patients
Farzad Rahmani, Shiva Salmasi, Haniyeh Ebrahimi Bakhtavar
Archives of Clinical Infectious Diseases (2022) Vol. 16, Iss. 6
Open Access
Previous Page - Page 2

Scroll to top